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Abstract
Background: Optimisation of genes has been shown to be beneficial for expression of proteins
in a range of applications. Optimisation has increased protein expression levels through improved
codon usage of the genes and an increase in levels of messenger RNA. We have applied this to an
adenovirus (ad)-based vaccine encoding structural proteins (E3-E2-6K) of Venezuelan equine
encephalitis virus (VEEV).
Results: Following administration of this vaccine to Balb/c mice, an approximately ten-fold increase
in antibody response was elicited and increased protective efficacy compared to an ad-based
vaccine containing non-optimised genes was observed after challenge.
Conclusion: This study, in which the utility of optimising genes encoding the structural proteins
of VEEV is demonstrated for the first time, informs us that including optimised genes in gene-based
vaccines for VEEV is essential to obtain maximum immunogenicity and protective efficacy.
Background
Venezuelan equine encephalitis virus (VEEV) is a positive-
stranded, enveloped, RNA virus of the genus Alphavirus in
the family Togaviridae. VEEV causes a disease in humans
characterized by fever, headache, and occasionally
encephalitis. It is the cause of recent outbreaks in South
America [1] and is considered to be a potential biological
weapon [2-6].
There is a complex variety of different serogroups of VEEV.
Only serogroup I varieties A/B and C have caused major
outbreaks involving hundreds of thousands of equine and
human cases [1]. Serogroups II through VI and serogroup
I varieties D, E and F are enzootic strains, relatively aviru-
lent in equines and not usually associated with major
equine outbreaks, although they do cause human illness
which can be fatal [7].
There is currently no vaccine licensed for human use to
protect against infection with VEEV, although two vac-
cines have been used under Investigational New Drug sta-
tus in humans. TC-83, a live-attenuated vaccine, and C-
84, a formalin-inactivated version of TC-83, are not con-
sidered suitable for use because of poor immunogenicity
and safety [8]. A further live-attenuated vaccine, V3526,
derived by site-directed mutagenesis from a virulent clone
of the IA/B Trinidad Donkey (TrD) strain of VEEV has
recently been developed. V3526 has been shown to be
effective in protecting rodent and nonhuman primates
against virulent challenge [9-11] but demonstrated a high
level of adverse events in phase I clinical trials [12].
We have previously developed adenovirus (ad)-based vac-
cines which encode the structural proteins of VEEV. The
structural proteins of VEEV (core, E3, E2, 6K and E1) are
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initially translated from a 26S subgenomic RNA as a single
polyprotein. Following proteolytic cleavage, individual
proteins are produced that are incorporated into the
mature virion [13]. The most potent immunogen, E2,
when co-expressed with E3 and 6K by the adenoviral vec-
tor, is able to confer protective efficacy in mice against
lethal aerosol challenge [14]. For protection against VEEV,
the antibody response is the principal correlate of protec-
tion [15]. An ad-based vaccine approach is additionally
advantageous because of the ability to administer the vac-
cine by a mucosal route, eliciting immunity important for
protection against aerosol challenge [16]. Our previously
constructed recombinant adenovirus expressing E3-E2-6K
genes from VEEV serotype IA/B (RAd/VEEV#3) was able to
confer 90–100% protection against 100LD50 of strains IA/
B, ID and IE of VEEV. However, it was less protective
against higher challenge doses and requires three intrana-
sal doses. Therefore, we have examined methods for
improving the immunogenicity of this vaccine candidate.
Methods for optimising genes are sophisticated and
becoming increasingly established for a variety of applica-
tions such as expression in prokaryotes, yeast, plants and
mammalian cells [17]. Codon usage adaptation is one
method of increasing the immunogenicity of epitope-
based vaccines as it can enhance translational efficiency.
Codon bias is observed in all species and the use of selec-
tive codons in genes often correlates with gene expression
efficiency. Optimal codons are those that are recognised
by abundant transfer RNAs (tRNAs) with tRNAs expressed
in lower levels being avoided in highly expressed genes. A
prominent example of successful codon adaptation for
increased mammalian expression is green fluorescent pro-
tein from the jellyfish Aequorea victoria [18]. However, as
well as influencing translation efficiency through more
appropriate codon usage, the levels of messenger RNA
(mRNA) available can also have a significant impact on
the expression level. Increasing the RNA levels by meth-
ods such as optimisation of GC content, and removal of
cis-acting RNA elements that negatively influence expres-
sion can also be achieved through the rational design of
genes. Because alteration of these parameters is a multi-
task problem and cannot be achieved as effectively
through linear optimisation, we used multi-parameter
optimization software (GeneOptimizer™, Geneart GmbH,
Regensburg) which allows different weighting of the con-
straints and evaluates the quality of codon combinations
concurrently.
This is the first demonstration of the optimisation of
structural genes of the VEEV. We have both codon adapted
and gene optimised the E3-E2-6K genes for expression in
mammalian cells from an ad-based vaccine. We show that
this process can improve antibody levels by up to ten-fold
following administration of the vaccine to mice and that
this confers increased protection from virus challenge.
This study provides important information to inform the
design of vaccines for VEEV, which may be applied to pre-
clinical VEEV vaccines such as ad-based vaccine [14], DNA
vaccines [19-21], and sindbis virus-based vaccine vectors
[22].
Results
Optimisation of genes expressing E3-E2-6K of VEEV
The genes encoding the structural proteins, E3-E2-6K,
were optimised using GeneOptimizer™ (Geneart GmbH,
Regensburg). This included codon usage adaptation, opti-
mal for mammalian expression. One measure of codon
quality is the Codon Adaptation Index (CAI), a measure-
ment for the relative adaptiveness of the codon usage of a
gene towards the codon usage of highly expressed genes.
The CAI scores of the wildtype and optimised genes were
0.75 and 0.98 respectively. Additionally, the optimised
gene had an increased GC content of 61% (compared to
52%) and 4 prokaryotic inhibitory motifs, 3 cryptic splice
donor sites and 3 RNA instability motifs (ARE) were
removed. The new gene sequence (VEEV#3-CO) is aligned
with the wild-type sequence in figure 1.
RAd/VEEV#3-CO virus expresses VEEV antigen
An adenovirus construct was prepared which expresses the
optimised gene sequence (RAd/VEEV#3-CO). Staining of
fixed HEK 293 cells infected with RAd/VEEV#3-CO with
mouse polyclonal anti-VEEV antibody produced a strong
fluorescence absent from uninfected cells (not shown) or
cells infected with empty adenovirus (RAd) (Figure 2).
This confirms the expression of VEEV antigen. RAd/
VEEV#3-CO also gave strong fluorescence in infected HEK
293 cells stained with VEEV E2-specific monoclonal anti-
bodies 1A3A-9, 1A4A-1 and 1A3B-7, confirming expres-
sion of the E2 structural protein (data not shown). None
of the monoclonal antibodies reacted with RAd infected
cells. Antigen expression levels were quantitatively ana-
lysed by ELISA using three different detection antibodies,
which indicated that the gene optimised adenovirus con-
struct expressed increased levels of antigen compared to
the non-gene optimised adenovirus construct (Figure 3).
Optimised ad-based vaccine elicits an increased anti-VEEV 
immune response compared to non-optimised
It was reasoned that the increased antigen expression of
the codon-optimised vaccine would lead to an increased
VEEV-specific immune response. Mice were immunised
on days 0 and 7 with 106 pfu and on day 21 with 103 pfu
of ad-based vaccines and sera were analysed after 2 doses
(day 16) and after 3 doses (day 23). The suboptimal dos-
ing regimen as compared to that used previously [14] was
designed to allow effective demonstration of improved
vaccine efficacy in our animal challenge model. At both
timepoints, the ad-based vaccine with optimised genesVirology Journal 2009, 6:118 http://www.virologyj.com/content/6/1/118
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induced approximately 10-fold more VEEV-specific anti-
body than the non-optimised equivalent (Figure 4). This
effect was statistically significant (p < 0.0001, Two way
ANOVA).
Optimised ad-based vaccine confers protection in mice 
against homologous VEEV challenge
Groups of 10 mice were challenged by the aerosol route
with VEEV (serogroup IA/B). Optimised vaccine signifi-
cantly protected more mice against homologous virus
challenge (90% survival) than either non-optimised vac-
cine (20% survival) or empty adenovirus (0% survival) (p
= 0.001 and p = 0.0001 respectively, Mantel-Haenszel
Logrank) (Figure 5).
Discussion
Previous efforts to improve the immunogenicity of an ad-
based vaccine for use against VEEV have been unreward-
ing. Adjuvants such as CpG and interferon alpha, have not
only failed to improve immune responses but have
increased the vector-specific response, potentially remov-
ing the possibility of repeated booster doses [23,24]. We
have also shown that although a DNA vaccine can effec-
tively prime the immune response prior to an ad-based
vaccine, heterologous prime-boost appeared to offer little
advantage over homologous adenovirus boosting [20].
We therefore reasoned that further optimisation of the
components of the ad-based vaccine may improve
immune responses.
Gene optimisation has been shown to be effective for a
number of treatment applications where a protein is syn-
thesised in vivo following gene delivery and is becoming
routinely used for a range of applications [25-27]. For
example, codon optimisation of the gene for the Respira-
tory syncytial virus F protein expressed from a DNA vac-
cine improved the performance relative to wild-type.
Stronger antibody responses and better control of virus
Optimised sequence of VEEV structural genes Figure 1
Optimised sequence of VEEV structural genes. The VEEV structural genes E3-E2-6K were optimised for expression by 
the addition of Kozak sequences, adaptation to optimal codon usage and removal of negative cis-acting sites using GeneOpti-
mizer™. The optimised and wildtype sequence were aligned using Clone Manager 9. Areas highlighted in green indicate areas 
of identical sequences.Virology Journal 2009, 6:118 http://www.virologyj.com/content/6/1/118
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replication after challenge was observed in the Balb/c
mouse model [28]. Codon optimisation of the Ag85B
gene which encodes the sceretory antigen of Mycobacte-
rium tuberculosis has also proved beneficial [29]. A stronger
Th1-like and cytotoxic T cell immune response in Balb/c
mice resulted in a increased protective efficacy in an aero-
sol infection model. Codon usage adaptation of the gag
protein of HIV delivered by a DNA vaccine increased gene
expression by 10-fold compared to wild-type. A substan-
tially increased humoral and cellular immune response in
Balb/c mice was elicited, which was independent of the
route of administration [30]. Similarly, optimisation of
the Pr55gag genes in a DNA vaccine substantially
increased gene expression, largely due to increased mRNA
stability of the optimised transcripts [31]. Gene optimised
HIV genes are currently encoded in DNA vaccine con-
structs undergoing human clinical trials [32,33]
Genes delivered by other platforms have also been opti-
mised. For example, vaccinia viral vectors encoding the
optimised HIV genes Gag-Pol-Nef are effective in small
animal models and humans [32,34,35]. Finally, it has
been demonstrated that the benefits of gene optimisation
may be particularly acute where two of these approaches
are combined in a prime-boost immunisation regimen
[32,33].
In this study, we have focused our efforts on ad-based vac-
cines. Because ad-based vaccines allow in vivo synthesis of
the antigen, a wide range of immune responses can be
elicited. We have included a gene optimised version of the
major antigenic determinant for VEEV, E2, along with the
chaperone proteins E3 and 6K within our ad-based vac-
cine. Delivery of this antigen by the ad-based vaccine is
able to elicit the principle correlate of protection, a VEEV-
specific antibody response [36-40]. CD4+ T cells [41], αβ
TCR-bearing T cells [42], cytokine responses and mucosal
immunity following intranasal delivery [16] may also be
initiated, though these mechanisms are believed to be of
minor importance relative to antibody responses.
There are relatively few published methods for signifi-
cantly enhancing the performance of ad-based vaccines.
Some success has recently been achieved with a comple-
ment-based molecular adjuvant (mC4 bp). However, suc-
cessful application of this to malaria vaccines has yet to
prove universally applicable [43]. Gene optimisation has
shown promise for a number of infectious diseases. For
example, ad-based malaria vaccines have been developed
containing malarial antigens optimised for expression in
mammalian cells. Codon adaptation significantly
increased the expression level of Plasmodium antigen in
mammalian cells [44]. In another study developing an ad-
based avian influenza (AI) vaccine, it was found that a
synthetic AI H5 gene with codons optimised to match the
chicken tRNA pool was more immunogenic than it's
counterpart without codon-optimisation [45]. Further-
more, an ad-based vaccine expressing gene optimised SIV
mac239 gag gene was chosen to demonstrate the potential
utility of ad-vectors derived from rare serotypes to elicit
immune responses in the presence of pre-existing anti-
Ad5 immunity [46].
Conclusion
In the current study, we are able to reproduce beneficial
effects on vaccination efficacy of gene optimisation, for
the first time with structural genes from the Alphavirus,
VEEV. This is significant because while previous attempts
to improve the protective efficacy of ad-based vaccines for
this infectious disease have proven unsuccessful
[20,23,24], we have increased both the immune response
and protective efficacy of this vaccine through gene opti-
misation. An ad-based vaccine for VEEV may be particu-
larly attractive given the increased inherent safety of this
approach compared to live-attenuated vaccines and the
potential of ad-based vaccines to be multivalent, poten-
tially including genes from other alphaviruses such as
western and eastern equine encephalitis viruses and
chikungunya.
Methods
Plasmids, cells and viruses
Plasmid pVEEV#3 was previously constructed [14]. It con-
tains the E3-E2-6K structural genes from the TC-83 strain
of VEEV (attenuated TrD strain) with three mutations
changing the sequence to that found in the virulent TrD
strain. This gene sequence was replaced by the optimised
Expression of VEEV proteins from recombinant adenoviruses Figure 2
Expression of VEEV proteins from recombinant ade-
noviruses. HEK 293 cells were infected with RAd (a) or 
RAdVEEV#3-CO (b) and stained with polyclonal anti-VEEV 
followed by anti-mouse whole molecule IgG conjugated to 
FITC.
(a)  
(b)Virology Journal 2009, 6:118 http://www.virologyj.com/content/6/1/118
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gene sequence to produce the plasmid pVEEV#3-CO. The
E3-E2-6K gene sequence was optimised and synthesised
by Geneart GmbH (Regensburg, Germany) and then
cloned into the pVEEV#3 backbone using the Bam HI sites
to create the plasmid pVEEV#3-CO. Recombinant adeno-
virus (RAd/VEEV#3-CO) was constructed and purified as
described previously for RAd/VEEV#3 [14]. The optimised
gene sequence in the recombinant ad was characterised by
sequencing. The viral DNA of RAd/VEEV#3-CO was
extracted using the QiaAmp DNA blood mini kit (Qiagen)
and the E3-E2-6K genes were PCR amplified. This was
then cloned into pCR®4-TOPO® (Invitrogen) for sequenc-
ing (Lark Technologies, Inc). Empty adenovirus contain-
ing no VEEV genes is designated RAd [14].
HEK 293 and A549 cell lines (European Collection of Ani-
mal Cell Cultures, UK) were propagated by standard
methods using the recommended culture media. VEEV
serogroup IA/B (Trinidad donkey; TrD) was kindly sup-
plied by Dr. B. Shope (Yale Arbovirus Research Unit, Uni-
versity of Texas, Austin, Texas, USA). Virulent virus stocks
were prepared and titred as previously described [14].
Immunofluorescence
Recombinant adenoviruses were tested for expression of
VEEV proteins by immunofluorescence. HEK 293 cell
monolayers in T25 flasks were infected with the recom-
binant ads or empty ad vector (RAd) for 48 hours at an
MOI of 1. Cells were then harvested, washed and resus-
pended in PBS. The suspension (5 μl) was spotted onto
glass slides which were then air dried and fixed in acetone
at -20°C for 15 minutes. The slides were reacted for 1 hour
at 37°C with a 1/400 dilution of mouse polyclonal anti-
VEEV antibody in PBS/1% FCS or 10 μg/ml of the E2-spe-
cific monoclonal antibodies 1A3A-9, 1A4A-1 and 1A3B-7
in PBS/1% FCS. Mouse polyclonal anti-VEEV antibody
was a kind gift from Dr. B. Shope of the Yale Arbovirus
Research Unit, University of Texas, Austin, Texas, USA and
E2-specific monoclonal antibodies were a kind gift of Dr.
J.T. Roehrig, Division of Vector-Borne Infectious Diseases,
CDC, Fort Collins, Colorado, USA. After three washes in
PBS, cells were stained for 1 hour at 37°C with FITC-
labelled anti-mouse whole molecule IgG (Sigma) diluted
1/800 in PBS/1%FCS. The slides were washed a further
four times in PBS before being mounted in 50% glycerol
and examined using a UV microscope.
ELISA
Mouse sera, harvested from the marginal tail vein or by
cardiac puncture, were assayed for VEEV-specific antibod-
ies using sucrose density gradient-purified, β-propiolac-
tone-inactivated antigen from strain TC-83 [14].
Immunoglobulin concentrations were estimated by com-
parison of the absorbance values generated by diluted
serum samples (three replicates) with a standard curve
prepared from dilutions of mouse IgG (Sigma, U.K.). To
examine the expression of VEEV structural proteins, con-
fluent monolayers of A549 cells in T25 flasks were
infected with RAd60, RAd/VEEV#3 or RAd/VEEV#3-CO
(m.o.i. 1000) and incubated for 48 hours. Antigen was
then prepared from cells by detergent extraction [14] and
used to coat ELISA plates (starting dilution of 1/100,
diluted 1/2 in coating buffer until 1/12800). VEEV E2 pro-
tein was detected using 10 μg/ml 1A4A1, 1A3B7 or
Antigen production by RAd/VEEV#3 and RAdVEEV#3-CO Figure 3
Antigen production by RAd/VEEV#3 and RAd-
VEEV#3-CO. A549 cells were infected with adenovirus 
constructs, harvested 48 hours later and the cell pellets 
detergent extracted. Extracted antigens were tested by 
ELISA against VEEV monoclonal antibodies, 1A4A1, 1A3B7 
and 1A4D1. Error bars represent the 95% CI of the assay.
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1A4D1 followed by a 1/4000 dilution of HRP-labelled
anti-mouse whole molecule IgG (Immunologicals
Direct).
Animals, immunisation and challenge with virulent VEEV
Groups of 10 Balb/c mice, 6–8 weeks old (Charles River
Laboratories, UK) were immunised intranasally under
halothane anaesthesia on days 0 and 7 with 106 pfu and
on day 21 with 103 pfu of RAd/VEEV#3, RAd/VEEV#3-CO
or RAd in 50 μl PBS. Seven days after the final immunisa-
tion, the animals were challenged via the airborne route
by exposure for 20 min to a polydisperse aerosol gener-
ated by a Collison nebuliser [47]. Mice were contained
loose within a closed box during airborne challenge. The
virus dose (100 LD50) was calculated by sampling the air
in the box and assuming a respiratory minute volume for
mice of 1.25 ml/g [48]. After challenge, mice were
observed twice daily for clinical signs of infection (pilo-
erection, hunching, inactivity, excitability and paralysis)
by an observer who was unaware of treatment allocations.
In accordance with UK Home Office requirements and as
previously described, humane endpoints were used [49].
These experiments therefore record the occurrence of
severe disease rather than mortality. Even though it is rare
for animals infected with virulent VEEV and showing
signs of severe illness to survive, our use of humane end-
points should be considered when interpreting any virus
dose expressed here as 50% lethal doses (LD50).
Statistical methods
Statistical analysis was performed using GraphPad Prism
version 4.03 for Windows (GraphPad Software, San
Diego, CA, USA, http://www.graphpad.com). All data was
normalised using a log transformation. Two-way ANOVA
with Bonferroni's Multiple Comparison Test and statisti-
cal analysis of survival using the Mantel-Haenszel logrank
test were performed as detailed in the Results section.
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